DWA
AVTX icon

Dorsey Wright & Associates’s Avalo Therapeutics AVTX Stock Holding History

Dorsey Wright & Associates’s Portfolio AVTX Stock Details AVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-1
Closed -$11K – 288
2019
Q1 		$11K Hold
1
– – ﹤0.01% 164
2018
Q4 		$12K Hold
1
– – ﹤0.01% 244
2018
Q3 		$15K Buy
+1
New +$13.1K ﹤0.01% 217

Other funds holding AVTX

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
EI
EAM Investors Solana Beach, California $866M AUM 377.14% 1-Year Est. Return

Dorsey Wright & Associates's AVTX Position: Q2 2019 in Review

Dorsey Wright & Associates sold out of Avalo Therapeutics (AVTX) in Q2 2019, closing a stake of 1 share — an estimated $11K sold.

Dorsey Wright & Associates first reported a position in AVTX in Q3 2018 and held it in 3 quarters. The position peaked at $15K in Q3 2018. 36 funds tracked by Wall St. Rank hold AVTX as of Q2 2019.

  • Dorsey Wright & Associates reported no remaining Avalo Therapeutics position as of Q2 2019 after selling out during the quarter.
  • Dorsey Wright & Associates sold 1 Avalo Therapeutics share in Q2 2019, an estimated $11K.
  • Dorsey Wright & Associates first reported a position in Avalo Therapeutics in Q3 2018 and held it in 3 quarters.
  • Dorsey Wright & Associates's Avalo Therapeutics position peaked at $15K in Q3 2018.
  • 36 funds tracked by Wall St. Rank held Avalo Therapeutics as of Q2 2019.

Based on Dorsey Wright & Associates's 13F filing for Q2 2019, filed 2 Jul 2019.